CStone Pharmaceuticals (FRA:PH4)

Market Cap	988.27M +170.6%
Revenue (ttm)	24.07M -55.6%
Net Income	-44.82M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	150
Open	0.6500
Previous Close	0.6300
Day's Range	0.6500 - 0.6550
52-Week Range	0.2300 - 1.3500
Beta	n/a
RSI	64.61
Earnings Date	Mar 26, 2026

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 131
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PH4

Financial Performance

In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.

Financial numbers in CNY